London South East were joined at their final live event of the year by Suzanne Dilly, CEO at AIM-listed ValiRX (VAL), the cancer and women's health drug developer which is also hoping to be become a service company or CRO to the pharmaceutical industry, generating additional revenue streams for the business.

What ValiRX does is take very early stage discoveries from universities or health charities and take these therapeutic development programmes in the fields of oncology or womens health and make them clinic-ready and partnership-ready.

A letter of intent to licence Val201 was signed in early November 2021 with TheoremRx Inc, a SPV, special purpose vehicle. briefly, VAL201 is a short peptide being studied as a potential treatment for prostate cancer. The potential value of the deal would be in excess of $61 million dollars US plus royalties for the first cancer indication, with 37.5M for each later indication.

Suzy confirmed that she thought this deal would be signed and become binding by the year-end or soon after, and the revenue streams generated by the deal would finance the new strategy. The new strategy involves data, which is key to clinical breakthroughs. Data generated from the ValiRx labs could better focus their drug development pipeline and be used on behalf of others.